ArticleLeukemia2023

RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.

J M O'Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.